Tabula Rasa HealthCare, Inc. short interest in 2023
In 2023, Tabula Rasa HealthCare, Inc.'s disclosed short interest ran from 4.50% of shares outstanding on 13 Jan 2023 to 2.68% on 31 Oct 2023, a change of -1.82 percentage points. The year's high was 6.43% on 15 Feb 2023 and its low 2.68% on 31 Oct 2023, averaging 4.50% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 40.28 days on 15 Feb 2023. Full history: Tabula Rasa HealthCare, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023
2023 in figures
- Start of year
- 4.50% (13 Jan 2023)
- End of year
- 2.68% (31 Oct 2023)
- Change
- -1.82 pp
- High
- 6.43% (15 Feb 2023)
- Low
- 2.68% (31 Oct 2023)
- Average
- 4.50%
- Highest days to cover
- 40.28 (15 Feb 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 4.50% | 20.83 | |
| 31 Jan 2023 | 6.42% | 14.03 | results (8-K) |
| 15 Feb 2023 | 6.43% | 40.28 | |
| 28 Feb 2023 | 6.27% | 29.66 | |
| 15 Mar 2023 | 6.09% | 19.93 | results (8-K), 10-K filed |
| 31 Mar 2023 | 6.30% | 14.49 | |
| 14 Apr 2023 | 6.34% | 7.19 | results (8-K) |
| 28 Apr 2023 | 5.92% | 21.08 | |
| 15 May 2023 | 5.14% | 12.81 | results (8-K), 10-Q filed |
| 31 May 2023 | 4.05% | 8.45 | |
| 15 Jun 2023 | 3.86% | 3.66 | |
| 30 Jun 2023 | 3.84% | 6.41 | |
| 14 Jul 2023 | 3.95% | 10.79 | |
| 31 Jul 2023 | 3.78% | 11.69 | |
| 15 Aug 2023 | 3.58% | 1.03 | results (8-K), 10-Q filed |
| 31 Aug 2023 | 2.82% | 1.38 | |
| 15 Sep 2023 | 2.72% | 2.09 | |
| 29 Sep 2023 | 2.69% | 2.46 | |
| 13 Oct 2023 | 2.71% | 5.01 | |
| 31 Oct 2023 | 2.68% | 2.30 |
See also: Tabula Rasa HealthCare, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.